ライフサイエンスコーパス: colposcopy

1 elial lesion (LSIL; benchmark indication for colposcopy).

2 ested positive on any test were referred for colposcopy.

3 se with LSIL), possibly warranting immediate colposcopy.

4 by Luminex assays, and STI clinical signs by colposcopy.

5 nd cervical samples from 72 women undergoing colposcopy.

6 43 cytology specimens from women referred to colposcopy.

7 r) are acquired from 44 patients at clinical colposcopy.

8 nal/cervical epithelial integrity changes on colposcopy.

9 e at 12 months was as effective as immediate colposcopy.

10 tive screening test results was referred for colposcopy.

11 tected by Pap test to determine the need for colposcopy.

12 any of the screening tests were referred for colposcopy.

13 r similar proportions (approximately 39%) to colposcopy.

14 ere followed semiannually with Pap tests and colposcopy.

15 included a Pap test, a test for HPV DNA, and colposcopy.

16 Of the 2,725 women who underwent enrollment colposcopy, 412 of 472 (87.3%) diagnosed with histologic

17 Women were referred for colposcopy according to a protocol.

18 observational study of 690 women referred to colposcopy after abnormal cervical cancer screening resu

19 Six underwent colposcopy and 4 required some form of destructive thera

20 cal cancer screening results are referred to colposcopy and biopsy for diagnosis of cervical cancer p

21 screening test results and were referred for colposcopy and biopsy.

22 ophytic condylomata acuminata-should undergo colposcopy and biopsy.

23 erence sponsored by the American Society for Colposcopy and Cervical Pathology (ASCCP).

24 can Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Soci

25 bnormal Pap smear by the American Society of Colposcopy and Cervical Pathology.

26 Colposcopy and diagnostic biopsies were done on women wi

27 to patients diagnosed with high-grade SIL on colposcopy and referral Pap smear.

28 cological examination twice yearly-including colposcopy and tests for human papillomavirus DNA in cer

29 compared in HPV-positive women who underwent colposcopy and were treated by LEEP (n = 195) and those

30 ing with those HPV16/18 positive referred to colposcopy and with dual-stained cytology triage for OHR

31 ing with those HPV16/18 positive referred to colposcopy and with LBC triage for other oncogenic (OHR)

32 rs were examined every 4 months by cytology, colposcopy, and HPV DNA status.

33 ion), semiannual Papanicolaou smears, annual colposcopy, and semiannual colposcopy--were considered.

34 rus (HPV) vaccination on cervical screening, colposcopy, and treatment is incompletely understood.

35 illance by repeat HPV testing, cytology, and colposcopy at 12 months.

36 Women who underwent colposcopy at baseline (n = 2,780) were grouped into 20

37 isk cases can be identified and referred for colposcopy based on a single screening.

38 population of patients (n=988) referred for colposcopy because of a cervical Pap cytology result of

39 Of 133 eligible participants, 41 underwent colposcopy because of a positive result for HPV of the c

40 ee-and-treat protocol, patients referred for colposcopy because of an abnormal Pap smear in cervical-

41 ears with cytologic testing and adherence to colposcopy/biopsy referrals were associated with the hig

42 women with SLE, 67 with abnormal smears from colposcopy clinics, and 15 community subjects with norma

43 y incorporating repeat cytology or immediate colposcopy conducted biennially.

44 Annual colposcopy cost more but provided no additional benefit

45 nt among HIV-negative MSM, and anoscopy with colposcopy did not increase the detection rate of rectal

46 ulvovaginal swab specimens and collection of colposcopy-directed biopsy specimens.

47 Papanicolaou smear screening, and semiannual colposcopy exceeded $375,000 per QALY saved.

48 or a cytological result of ASC-US: immediate colposcopy; human papillomavirus (HPV) triage, which inc

49 cytology at 6 and 12 months and referral for colposcopy if a repeat abnormal result occurs; and recla

50 papillomavirus (HPV) triage, which includes colposcopy if high-risk HPV types are detected; repeat c

51 f additional lesion-directed biopsies during colposcopy increased detection of histologic HSIL, regar

52 g rounds, including detection of disease and colposcopies, limits our ability to determine the net be

53 rporate DVI or HPV DNA testing and eliminate colposcopy may offer attractive alternatives to cytology

54 Cytology of a specimen taken at colposcopy (mild dyskaryosis or worse) had 88.9% sensiti

55 Clustering results suggested that colposcopy missed a prevalent precancer in many women wi

56 Compared with referral for colposcopy of all women with ASCUS or higher, signal amp

57 HPV-based algorithm including the immediate colposcopy of HPV-positive women, and then repeat Pap te

58 The approval recommended either colposcopy or a Pap test for patients with specific high

59 nderwent periodic Papanicolaou testing, with colposcopy or biopsy for detected abnormalities.

60 Whether colposcopy or repeated testing is recommended for hrHPV-

61 gative cytology were randomised to immediate colposcopy or to surveillance by repeat HPV testing, cyt

62 collected from 135 patients attending either colposcopy or women's clinics in Guayaquil, Ecuador, who

63 rogram of 2 repeat cytology tests, immediate colposcopy, or DNA testing for high-risk types of human

64 o more likely to be HPV-16 DNA positive than colposcopy patients (P < 0.05).

65 SLE and colposcopy patients were more likely (P < 0.05) to be HP

66 All HPV-16 DNA sequences from 6 SLE and 5 colposcopy patients were the European-type variant.

67 All women not selected for colposcopy received their results and exited the study.

68 We aimed to assess colposcopy referral and CIN2+ detection rates for HPV-sc

69 The main outcomes were colposcopy referral and detected CIN2+ rates at baseline

70 sis and the 4-year cumulative proportions of colposcopy referral and treatment by vaccination arm wer

71 Colposcopy referral and treatment were reduced by 21.3%

72 to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in t

73 ection rates of CIN2+ without increasing the colposcopy referral rate.

74 t be associated with a transient increase in colposcopy referral rates in the first round of HPV scre

75 Colposcopy referral was reduced by 7.9% (P = 0.03) and t

76 U.S. consensus risk threshold for immediate colposcopy referral.

77 Colposcopy showed no abnormal findings with either tampo

78 In women who had colposcopy, the cobas HPV test was more sensitive than l

79 ansport medium from 1,099 women referred for colposcopy: the Hybrid Capture 2 (Qiagen), Cobas (Roche)

80 tailed genital examination and anoscopy with colposcopy to detect herpes lesions.

81 m the screening and the colposcopy visits, 7 colposcopy triage strategies were defined and evaluated.

82 HPV typing has been recommended for colposcopy triage, but it is not clear which combination

83 d to cytology and HPV test results until the colposcopy visit was completed.

84 tion test results from the screening and the colposcopy visits, 7 colposcopy triage strategies were d

85 trually for a broad panel of microorganisms, colposcopy was performed, and diary reports were collect

86 lly for a broad panel of microorganisms, and colposcopy was performed.

87 ou smears, annual colposcopy, and semiannual colposcopy--were considered.

88 liquid-based cytology, followed by immediate colposcopy with a reduction of 87% and 91%, respectively

89 Colposcopy with a single biopsy can miss identification

90 ssay and polymerase chain reaction, and anal colposcopy with biopsy of lesions.

91 by the PCR method and 92 underwent screening colposcopy with biopsy prior to knowing the HPV PCR resu